TRIB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Trinity Biotech PLC (TRIB) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators are neutral, there are no significant trading signals, and the financial performance shows no growth momentum. While the options data suggests bullish sentiment, the lack of recent news or catalysts makes this stock less compelling for immediate investment.
The MACD is slightly positive at 0.00642, suggesting weak bullish momentum, but it is contracting. RSI at 39.445 is neutral, indicating no overbought or oversold conditions. Moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 0.665, with resistance at 0.703.
Options data shows bullish sentiment with low put-call ratios. The stock has a 7.92% chance of increasing in the next month based on historical candlestick patterns.
No recent news or event-driven catalysts. Financials show no year-over-year growth in revenue, net income, or EPS. No recent insider or hedge fund activity, and no congress trading data available.
In Q3 2024, revenue was flat at $15,152,000 with no YoY growth. Net income remained negative at -$4,759,000, and EPS was -0.04. Gross margin was 35.44%, also showing no improvement YoY.
No data on analyst ratings or price target changes is available for TRIB.
